NMN vs NAD+: What 2 Head-to-Head Human Trials Found

NAD+ is the molecule your cells run on. NMN is one chemical step away from it. That is the whole difference, and it's why almost every product in this category sells a precursor rather than NAD+ itself.

Underneath that sits the question people are actually asking. If NMN converts into NAD+, and NAD+ drives the machinery that makes energy and repairs DNA, does taking NMN raise the NAD+ in your body? Two trials published in 2026 answered a large part of that, and the answer is stronger than this category's critics expected. It is also more specific than most labels suggest.

The short answer

• NAD+ is the molecule your cells run on. NMN is one enzyme step away from it, and that step is the whole reason this category sells a precursor rather than NAD+ itself
• Taken by mouth, NAD+ gets broken into smaller pieces before it reaches a cell, and those pieces are what cross the membrane. The precursor route is mechanical, not promotional
• Both raise blood NAD+. Christen and colleagues put NR and NMN head to head against a placebo in 65 adults over 14 days and found them comparable, with each roughly doubling it
• Plain nicotinamide, the cheap B3 form, didn't move it at all, which is what separates a precursor worth buying from one that isn't
• Published doses run from 100mg to 1,200mg a day. Yi and colleagues found 600mg did everything 900mg did over 60 days
• The brain result belongs to NR, not NMN. Cerebral NAD+ rose after 4 weeks on NR. NMN was tested at 8 days, moved nothing, and was dropped, so no 4-week brain data for NMN exists

Jump to: is it the same as NAD+ · what NAD+ does · why nobody sells oral NAD+ · what the trials measured · NMN or NR · does it reach the brain · dose · which one · common questions

Is NMN the same as NAD+?

No. NMN and NAD+ are two different molecules sitting one enzyme step apart. NAD+ is the coenzyme your cells actually use. NMN is the raw material they build it from, and an enzyme called NMNAT does the converting.

Supplement labels use the two names almost interchangeably, which is where most of the confusion starts. A bottle marketed as an NAD+ product is usually a bottle of precursor, and that isn't a trick. It's the only route that reliably gets anything into a cell.

The practical version: NMN is what you can absorb, NAD+ is what your body builds from it, and the conversion happens inside your cells rather than in the bottle.

What NAD+ actually does

NAD+ has two jobs. It is the carrier that moves electrons through the reactions your cells use to make energy, and it's the raw material a family of repair enzymes called PARPs consume when they mend breaks in your DNA. A second family, the sirtuins, can't work without it either. Both roles are textbook biochemistry and both predate the supplement industry by decades. Take NAD+ out of a cell and the cell stops working.

The part that matters for supplements is what happens next. Cells hold very little NAD+ at any moment. They rebuild it constantly, and most of that rebuilding runs through a recycling route biochemists call the salvage pathway. Nicotinamide becomes NMN. NMN becomes NAD+. Roos and colleagues, August 2021, in Signal Transduction and Targeted Therapy, laid this out in an open-access review whose authors declared no competing interests, which in a field where most explainers are written by people selling something is worth more than it sounds.

NMN isn't an exotic addition to your biology. It is an intermediate your cells already make and already use, sitting one enzyme away from the destination.

How are NAD+, NMN and NR related?

Nicotinamide riboside, sold as NR, is the other precursor you'll see. It enters cells and is converted to NMN first, which puts it one step further out. Nicotinamide, plain vitamin B3, sits at a similar distance.

Why nobody sells you oral NAD+ itself

The obvious question is why a supplement would bother with a precursor when it could just sell the destination. The answer is size and charge.

NAD+ is a large, charged molecule. Outside the cell, enzymes on the cell surface break it into smaller pieces, and it's those pieces that cross the membrane through their own transporters. The precursor is what gets in either way. Selling NAD+ orally means selling something that will be taken apart into precursors before it can be used.

Worth saying plainly, because the internet is confident about this and the internet is guessing: no human study appears to have directly measured whether oral NAD+ survives intact. The mechanism is well supported. The specific figures that circulate, usually some variant of "less than 5 percent survives," appear on marketing pages with nothing behind them. Treat the reasoning as sound and the percentage as folklore.

What the human trials actually measured

The 2026 trials are where this category earned something real, and they're worth going through one at a time.

The largest and best controlled is Christen and colleagues, January 2026, in Nature Metabolism. 65 healthy adults were randomly assigned to NMN, NR, plain nicotinamide or a placebo, and took it once daily for 14 days. NMN roughly doubled circulating NAD+ against placebo. NR did the same. Plain nicotinamide, the cheap B3 form, didn't move it at all, which is the finding that separates a precursor worth buying from one that is not.

Two details give that result weight. It had a placebo arm, which most of this literature doesn't. And it was run inside Nestlé's own research laboratory in Lausanne by Nestlé employees, a company with no stake in NMN winning, which makes a positive NMN result harder to wave away.

Yi and colleagues, February 2023, in GeroScience, ran the longest of the dose-ranging trials: 80 healthy middle-aged adults across placebo and three doses for 60 days. Blood NAD rose at every dose. Every NMN group also covered more ground in a six-minute walking test than the placebo group did, and scored better on quality of life. Two things belong beside that. The measurement was taken in serum, the fluid outside cells, and the lead author worked for the company whose product was being tested.

Yoshino and colleagues, June 2021, in Science, is the one that measured a functional outcome in tissue. 25 postmenopausal women with prediabetes took 250mg daily for 10 weeks against placebo, and muscle insulin sensitivity improved by roughly a quarter. That is a specific result in a specific group, and it hasn't been repeated in anyone else.

One trial gets quoted for something it never reported. Irie and colleagues, February 2020, in Endocrine Journal, gave 10 healthy men a single dose and watched them for five hours. It didn't measure NAD+. What rose were two breakdown products, which showed that oral NMN is absorbed and metabolized. That is a useful finding and it's not the one the pages citing it claim.

Should I take NMN or NAD+?

NMN, if the choice is only between those two and the form is a capsule. Oral NAD+ is taken apart before it reaches a cell, so what you absorb is precursor either way. The table below sets all three side by side, including NR, the other precursor you'll meet on a shelf.

Is NMN better than NR?

For years this argument ran without data. NMN sellers pointed at the step count. NR sellers pointed at a deeper shelf of human trials. Nobody had put the two in the same room at the same dose.

Two trials did that in 2026, and they disagree. That disagreement is the most useful thing on this page.

Berven and colleagues, January 2026, in iScience, gave 6 healthy adults both compounds in turn at 1,200mg daily. NR raised blood NAD about 161 percent over 8 days. NMN raised it about 69 percent. The researchers judged the gap wide enough that they dropped NMN and carried only NR into the later stages, writing that NR "produced a greater NAD increase, only NR was investigated further to reduce participant burden."

Christen's trial found no such gap. At 1,000mg daily for 14 days, in 65 people rather than six, the authors describe NR and NMN as raising circulating NAD+ comparably. Both roughly doubled it.

One small trial favors NR and one much larger one doesn't reproduce the difference. Doses, schedules and designs all differ, which is the ordinary reason trials disagree. The honest reading is that NR has the longer evidence record, NMN has now cleared the same placebo-controlled bar, and whether one genuinely beats the other in a human body isn't settled.

Read the marketing on this and you wouldn't know that. The NR brand promoting the Bergen result describes it as carried out with "no commercial involvement of any kind." No manufacturer funded it and the researchers bought both products at retail, so that's fair as far as it goes. The paper's own disclosure adds something the marketing doesn't: two of its senior authors are named inventors on international patent applications covering nicotinamide riboside as a treatment for Parkinson's disease. That isn't misconduct and it doesn't make the numbers wrong. It is the kind of thing a reader deserves to be told before deciding whose side of an argument to stand on.

Does NMN raise NAD+ in the brain?

Not on the evidence so far, and the trial that showed a brain effect used NR rather than NMN. That distinction goes missing in most write-ups of it.

The Bergen trial did something no NMN or NR study had done before. It measured NAD inside the living human brain, using magnetic resonance spectroscopy rather than a blood draw.

After 4 weeks of supplementation, cerebral NAD had risen measurably. That is the first direct human evidence that an oral precursor can raise NAD in the organ the whole longevity argument cares most about.

Two things keep it from being an NMN headline. The four-week arm used NR, because NMN had already been dropped. And in the eight-day stage where both were tested, neither compound moved brain NAD, which the authors attribute partly to the short window and partly to their scanner being less sensitive than a blood assay. That puts the finding with precursors as a class, and with NR specifically.

The finding still matters here, because the premise underneath every NMN label has been that an oral precursor can reach tissue and lift NAD there. Until 2026 that was an argument. It is now, at least once and at least in the brain, an observation.

How much NMN the trials actually used

Published human doses run from 100mg to 1,200mg.

Yi's trial is the most useful for anyone reading a label, because it tested three doses side by side over 60 days. Blood NAD rose at 300mg, at 600mg and at 900mg, and 900 did nothing that 600 had not already done. A label promising a very large number isn't obviously promising a larger result.

Yoshino used 250mg for 10 weeks, the lowest dose in the group and the one attached to a tissue-level result. Christen used 1,000mg for 14 days. Berven used 1,200mg, split into two doses a day, and reported that blood NAD climbed slowly and plateaued after about 2 weeks, then fell just as slowly once dosing stopped. That last point is practical: this isn't a molecule that does anything useful occasionally.

None of that is a dosing recommendation, and anyone taking medication or managing a health condition should talk to their own clinician first.

Does NAD+ really fall by half by age 50?

You will meet this number everywhere. It doesn't survive checking.

Pages repeating it either cite nothing, cite a newspaper article, or link to a paper that turns out to be a different paper. The most recent authoritative review, Vinten and colleagues, October 2025, in Nature Metabolism, describes age-related decline in human NAD+ as having been consistently observed in only a limited number of studies, and calls the body of human tissue data sparse. The measurements that do exist are smaller than half and they vary by tissue.

Something does change with age, and the honest version of that sentence is more useful than the invented one. It isn't a cliff at fifty. A category resting its pitch on a figure nobody can source is telling you something about the category.

What is the NMN transporter argument?

Grozio and colleagues, January 2019, in Nature Metabolism, reported that a gene called Slc12a8 encodes a dedicated NMN transporter, which would mean NMN enters cells directly rather than being converted first. NMN sellers cite it as settled. Schmidt and Brenner, July 2019, in the same journal, argued the methods didn't support the conclusion, and the original authors replied defending it.

The transporter dispute has never been resolved, and all of it is mouse work. Both sides also have money in the answer. Brenner disclosed in that rebuttal that he held stock in and advised ChromaDex, which sells the competing precursor. None of the pages currently ranking for this comparison mention that the dispute exists, let alone who funds which side of it.

Which one, then

If the question is which molecule sits closer to NAD+, it's NMN, and the chemistry isn't in dispute.

If the question is which one to take, the useful answer is that NAD+ itself is the weakest of the three orally, and that both precursors now clear a placebo-controlled bar in humans. NR has the longer record and the larger body of trials. NMN has the shorter step, a placebo-controlled doubling of circulating NAD+, a dose-response curve that flattens above 600mg, and one tissue-level result in a specific group of women.

What still hasn't been shown is an oral NMN dose lifting NAD+ inside human muscle or liver, and the single trial that looked at brain found nothing at 8 days. Those are the open questions, and they're laid out with their populations and caveats on the Healthspan Guide.

A smaller question sits underneath all of it, and this one does have a clean answer: does the capsule contain what the label says. That is worth settling before any of the rest matters, because a dose you can't verify isn't a dose. Our own NMN360 is tested by high-performance liquid chromatography and the certificate is published for the batch in your hand. What that number tells you is the identity and the amount. It doesn't tell you what NMN will do for you, because the trials above are still the whole of what anyone knows.

The category-wide version of that question, including which laboratories have tested NMN products against their labels and who paid for the testing, is in how to tell whether your NMN actually contains NMN.

Frequently asked questions

What is the difference between NMN and NAD+?

NAD+ is the coenzyme your cells use to make energy and repair DNA. NMN is the precursor they build it from, one enzyme step away. The difference matters when you're buying, because oral NAD+ is broken into smaller pieces before it can cross a cell membrane, and those pieces are precursors. Every product in this category is selling you a step on the same path.

Is NMN better than NAD+ as a supplement?

Taken by mouth, yes, and the reason is mechanical rather than promotional. NAD+ is a large charged molecule that gets broken into smaller pieces outside the cell, and those pieces are what actually cross the membrane. NMN is already one of those pieces. No trial has compared oral NMN against oral NAD+ directly, so this rests on biochemistry rather than on a head-to-head result.

Does NMN actually raise NAD+ levels in humans?

Yes, in blood, and that has now been shown against a placebo. Christen and colleagues, January 2026, found NMN roughly doubled circulating NAD+ across 14 days in 65 adults, and Yi and colleagues, February 2023, found it rose at 300, 600 and 900mg daily over 60 days. Whether an oral dose lifts NAD+ inside muscle or liver hasn't been demonstrated.

What is the difference between NMN and NR?

NR sits one enzyme step further from NAD+ and is converted into NMN inside the cell. Two 2026 trials compared them directly and disagreed: Berven and colleagues found NR raised blood NAD about 161 percent against about 69 percent for NMN in 6 adults over 8 days, while Christen and colleagues found the two comparable in 65 adults over 14 days. NR has the longer evidence record. Which is better in practice isn't settled.

Does NMN raise NAD+ in the brain?

Not in the only window anyone has tested. Berven and colleagues, January 2026, measured NAD inside the living human brain by magnetic resonance spectroscopy and found no change after 8 days on NMN. Cerebral NAD did rise measurably after 4 weeks in the same study, but that arm used NR only, so there's currently no four-week human brain data for NMN.

How much NMN did the trials use?

Published doses run from 100mg to 1,200mg daily. Yi and colleagues tested 300, 600 and 900mg over 60 days and found no additional gain above 600mg. Yoshino and colleagues used 250mg for 10 weeks. Blood NAD rises slowly and plateaus after about 2 weeks of daily dosing, so consistency matters more than size. None of this is a dosing recommendation, and anyone on medication should speak with their clinician.

Does NAD+ really drop by 50 percent by age 50?

That figure doesn't hold up. No page repeating it cites a study that supports it under checking, and the October 2025 review in Nature Metabolism describes the human tissue evidence for age-related decline as sparse and consistently observed in only a limited number of studies. Some decline appears real. Half by fifty isn't a documented finding.

Is NMN legal to sell in the United States?

Yes. The FDA reversed its earlier position in two letters dated September 29, 2025, confirming NMN isn't excluded from the dietary supplement definition, and issued confirming letters to ingredient suppliers in December 2025. A New Dietary Ingredient notification is still required. Several highly ranked pages still describe NMN as banned, which has been out of date since late 2025.

How long have people taken NMN safely?

The longest trials cited here ran 60 days and 10 weeks, and reported the doses were tolerated. Nobody has published a multi-year human safety study, because the research is too young for one to exist. That is a limit on what's known rather than a finding, and it's the reason anyone pregnant, nursing, on medication or managing a condition should talk to a clinician before starting.

Is NMN approved outside the United States?

It varies by country and universal legality should not be assumed. NMN isn't authorized as a novel food in the European Union, and an application is still under assessment in the United Kingdom. It is licensed for sale in Canada under narrow permitted claims. Check your own market before ordering.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is general information, not medical advice. Talk to your healthcare provider before starting any supplement, particularly if you are pregnant, nursing, managing a medical condition, or taking medication.